Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

The challenges of treating breast cancer in Brazil

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC

SABCS 2019 highlights

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Imaging for women who are high risk of breast cancer

Adding S-1 to post-operative endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC